Our Research

Houston Methodist COVID-19 Research Thumbnail
Coronavirus Disease 2019 (COVID-19) Research

Houston Methodist researchers are studying the novel coronavirus disease 2019. Read more...

At Houston Methodist, fostering innovations with the potential for clinical application is at the very heart of what we do. Our interdisciplinary teams of clinicians and researchers are committed to streamlining the process of translating discoveries into treatments and cures for our patients.


Learn more about how we are delivering on our commitment to leading medicine from the earliest phase of discovery in a lab to the testing new drugs or therapies in clinical trials.



You can find our most recent annual report here: 2021 HMAI Annual Report

Novel medical technology for craniomaxillofacial surgery is cleared by FDA for market

Doctor using AnatomicAligner, a new FDA-approved Methodist-built software program, on an iPad.

Houston Methodist recently reached a major milestone, receiving U.S. Food and Drug Administration (FDA) 510(k) clearance to market the AnatomicAligner, a novel, comprehensive software program used to improve planning for craniomaxillofacial (CMF) surgeries. Learn more>

Houston Methodist is first to treat COVID-19 with convalescent plasma therapy

Computer-generated image of a Coronavirus

Houston Methodist was the first in the nation to receive FDA approval to use convalescent plasma for COVID-19 patients and the first to publish a peer-reviewed study on the therapy, revealing 19 of 25 critically ill patients showed improvement. Learn more>


Researchers Identify Protein To Aid With Glioblastomas

Molecular Analysis Slide

In a recent study published in Nature Communications, Houston Methodist researchers, led by Kyuson Yun, PhDassociate professor of neurology, conducted a molecular analysis that identified a protein, S100A4, which could be a therapeutic target for restoring anti-tumor action of immune cells toward glioblastomas that have beguiled the immune system into protecting it.  Learn more>

Center for RNA Therapeutics Awarded Inno Fire Award

Inno Fire Awards Logo

The Center for RNA Therapeutics won the 2022 Houston Inno Fire Award from the Houston Business Journal for innovation in health care and life sciences. Learn more>


Latest News

Thursday, December 8, 2022 Improving bladder cancer trials and treatments goal of new $6 million CPRIT recruit
With a focus on expediting the development of early-phase clinical trials and enhancing chemoimmunotherapy responses in bladder cancer, genitourinary cancer translational scientist Keith Syson Chan, Ph.D., is joining Houston Methodist thanks to a $6 million Established Investigator recruitment grant...
Read more
Tuesday, October 4, 2022 Houston Methodist enters the metaverse with launch of new MITIEverse™ app
Exploring the heart from the inside out is now possible with a new app from Houston Methodist. Medical and scientific learners can access hands-on practice, remote assistance from experienced clinicians and more within the MITIEverse™, a new app devoted to health care education, training and innova...
Read more
Thursday, September 29, 2022 Improving hospital stays and outcomes for older patients with dementia through AI
By using artificial intelligence, Houston Methodist researchers are able to predict hospitalization outcomes of geriatric patients with dementia on the first or second day of hospital admission. This early assessment of outcomes means more timely interventions, better care coordination, more judicio...
Read more